Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 Life Science Investing
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics Life Science Investing
Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call Life Science Investing
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT Pharmaceutical Investing
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy Life Science Investing
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 Life Science Investing
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 Life Science Investing
Seer Board of Directors Issues Letter to Shareholders Setting the Record Straight Life Science Investing
Agility Robotics and Churchill Capital Corp XI Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination Life Science Investing
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment Life Science Investing
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
